Shanda Group Participates in Cordance Medical’s Oversubscribed $8M Seed Financing to Advance Focused Ultrasound Platform for Brain Disease Treatment
We are excited to join Cordance Medical’s oversubscribed $8M seed round led by Sonder Capital, and including, Angel Physicians Fund, R42 Group, The Sontag Foundation Innovation Fund, and the Brain Tumor Investment Fund.
Cordance Medical is pioneering a noninvasive focused ultrasound platform that can safely open the blood-brain barrier to deliver therapies for brain tumors and other neurological diseases. Cordance’s NeuroAccess™ device is designed for the ubiquitous infusion chair instead of requiring a lot of heavy, cumbersome equipment.
Our congratulations to the team at Cordance Medical!
You might also interested in
-
WhizAI Closes New Round with Investment from Shanda Group and AmerisourceBergen Bringing Total Capital Raised to $21 Million
SOMERSET, N.J.–(BUSINESS WIRE)–WhizAI, the first and only augmented analytics platform purpose built for the life sciences and healthcare industries, has […] -
Foundation Capital Invests in Vibe Capital, a New Venture Firm Built for Scrappy International Founders
Limited partners in Vibe Capital include Bessemer Venture Partners, Tribe Capital and Foundation Capital, as well as individuals including GSV […] -
Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC deal
One of Shanda’s portfolio companies, the digital treatment developer Pear Therapeutics, is taking the SPAC track, going public through a […]